106 related articles for article (PubMed ID: 23687783)
1. New skin cancer target could delay drug resistance.
Oncology (Williston Park); 2013 Mar; 27(3):164. PubMed ID: 23687783
[No Abstract] [Full Text] [Related]
2. Mechanisms of acquired resistance to targeted cancer therapies.
Lackner MR; Wilson TR; Settleman J
Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
[TBL] [Abstract][Full Text] [Related]
3. Melanoma genetics: the other side.
Bis S; Tsao H
Clin Dermatol; 2013; 31(2):148-55. PubMed ID: 23438378
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
Chandarlapaty S; Modi S
J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
[No Abstract] [Full Text] [Related]
5. Targeted therapies: the answer to individualized treatment?
Hutchinson L
Nat Clin Pract Oncol; 2007 Jun; 4(6):323. PubMed ID: 17534387
[No Abstract] [Full Text] [Related]
6. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
Cruzalegui F
Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
[No Abstract] [Full Text] [Related]
7. Targeted Therapies for Prostate Cancer.
Petrioli R; Francini E; Fiaschi AI; Laera L; Roviello G
Cancer Invest; 2015; 33(7):276-85. PubMed ID: 25951372
[TBL] [Abstract][Full Text] [Related]
8. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.
Richardson A; Kaye SB
Drug Resist Updat; 2005 Oct; 8(5):311-21. PubMed ID: 16233989
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy: overcoming drug resistance with clinical cancer genome.
Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH
Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
[No Abstract] [Full Text] [Related]
11. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
Wilting RH; Dannenberg JH
Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
13. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
14. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells.
Lin Y; Wang Z; Liu L; Chen L
Lung Cancer; 2011 Mar; 71(3):291-7. PubMed ID: 20599289
[TBL] [Abstract][Full Text] [Related]
15. Building better therapy for children with acute lymphoblastic leukemia.
Carroll WL; Raetz EA
Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
[TBL] [Abstract][Full Text] [Related]
16. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells.
Yuan G; Regel I; Lian F; Friedrich T; Hitkova I; Hofheinz RD; Ströbel P; Langer R; Keller G; Röcken C; Zimmermann W; Schmid RM; Ebert MP; Burgermeister E
Oncogene; 2013 Jan; 32(3):375-87. PubMed ID: 22370641
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Kim KB
Cancer; 2013 Feb; 119(3):477-80. PubMed ID: 22915026
[No Abstract] [Full Text] [Related]
18. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
Bellail AC; Hao C
Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
[No Abstract] [Full Text] [Related]
19. [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer].
Sasaki N; Takano M; Kudou K; Kita T; Kikuchi Y
Nihon Rinsho; 2004 Oct; 62 Suppl 10():582-6. PubMed ID: 15535312
[No Abstract] [Full Text] [Related]
20. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]